{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:36:32Z","timestamp":1787841392051,"version":"build-2784847793"},"reference-count":44,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Venetoclax, the best established BH3-mimetic, is a practice-changing proapoptotic drug in blood cancers in adults. In paediatrics the data are fewer but exciting results were recently presented in relapsed or refractory leukaemias demonstrating significant clinical activity. Importantly, the in-terventions could be potentially molecularly guided as vulnerabilities to BH3-mimetics were re-ported. Currently venetoclax is not incorporated into paediatric treatment schedules in Poland but it has been already used in patients that failed conventional therapy in Polish paediatric haemato-oncology departments. The aim of the study was to gather clinical data and correlates of all paediatric patients treated so far with venetoclax in Poland. We set out to gather this experience to help choose the right clinical context for the drug and stimulate further research. The questionnaire regarding the use of venetoclax was sent to all 18 Polish paediatric haemato-oncology centres. The data as available in November 2022 were gathered and analysed for the diagnoses, triggers for the intervention, treatment schedules, outcomes and molecular associations. We received response from 11 centres, 5 of which administered venetoclax to their patients. Clinical benefit, in most cases consistent with hematologic complete remission (CR), was reported in 5 patients out of ten, whereas 5 patient did not show clinical benefit from the intervention. Importantly, patients with CR included subtypes expected to show venetoclax vulnerability, such as poor-prognosis ALL with TCF::HLF fusion. We believe BH3-mimetics have clinical activity in children and should be available to pae-diatric haemato-oncology practitioners in well-selected applications.<\/jats:p>","DOI":"10.3390\/children10040745","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T03:25:11Z","timestamp":1681961111000},"page":"745","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-683X","authenticated-orcid":false,"given":"Katarzyna","family":"Bobeff","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-6947","authenticated-orcid":false,"given":"Agata","family":"Pastorczak","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-6627","authenticated-orcid":false,"given":"Zuzanna","family":"Urbanska","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walentyna","family":"Balwierz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, 30-663 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Juraszewska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, 30-663 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wachowiak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Transplantology, Pozna\u0144 University of Medical Sciences, Szpitalna 27\/33, 60-572 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7239-4035","authenticated-orcid":false,"given":"Katarzyna","family":"Derwich","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Transplantology, Pozna\u0144 University of Medical Sciences, Szpitalna 27\/33, 60-572 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Samborska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Transplantology, Pozna\u0144 University of Medical Sciences, Szpitalna 27\/33, 60-572 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Dachowska-Kalwak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Laguna","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Hematology, Independent Public Children\u2019s Teaching Hospital, Zwirki i Wigury 63A, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Malinowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Hematology, Independent Public Children\u2019s Teaching Hospital, Zwirki i Wigury 63A, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Smalisz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Hematology, Independent Public Children\u2019s Teaching Hospital, Zwirki i Wigury 63A, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Gozdzik","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant Center, Department of Clinical Immunology and Transplantology, University Children\u2019s Hospital, Jagiellonian University Collegium Medicum, Wielicka 265, 30-663 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Oszer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Urbanski","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-113X","authenticated-orcid":false,"given":"Maciej","family":"Zdunek","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-261X","authenticated-orcid":false,"given":"Tomasz","family":"Szczepanski","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Medical University of Silesia, 3-go Maja 13-15, 41-800 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-5851","authenticated-orcid":false,"given":"Wojciech","family":"Mlynarski","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-6969","authenticated-orcid":false,"given":"Szymon","family":"Janczar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36\/50, 91-738 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.26677","article-title":"Management of front line chronic lymphocytic leukemia","volume":"97","author":"Kutsch","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gibson, A., Trabal, A., McCall, D., Khazal, S., Toepfer, L., Bell, D.H., Roth, M., Mahadeo, K.M., Nunez, C., and Short, N.J. (2021). Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers, 14.","DOI":"10.3390\/cancers14010150"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e922","DOI":"10.1016\/S2352-3026(21)00270-2","article-title":"Harnessing the benefits of available targeted therapies in acute myeloid leukaemia","volume":"8","author":"Kantarjian","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","article-title":"Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: A post-hoc, propensity score-matched, cohort study","volume":"9","author":"Lachowiez","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: Phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMc2029153","article-title":"Azacitidine and Venetoclax in AML","volume":"383","author":"Chitikela","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_9","first-page":"592","article-title":"Venetoclax in AML: Efficacy confirmed","volume":"17","author":"Killock","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","first-page":"37","article-title":"Changing paradigms in the treatment of acute myeloid leukemia in older patients","volume":"20","author":"Bazinet","year":"2022","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e991","DOI":"10.1097\/MPH.0000000000002050","article-title":"Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma","volume":"43","author":"Baig","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: A phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41409-022-01877-2","article-title":"Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed\/refractory AML","volume":"58","author":"Pfeiffer","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"127.e1","DOI":"10.1016\/j.jtct.2022.11.022","article-title":"Targeted therapy with venetoclax and daratumumab as part of HSCT preparative regimen in children with chemorefractory acute myeloid leukemia: Venetoclax and daratumumab as part of HSCT preparative regimen for AD AML","volume":"29","author":"Klimentova","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2217\/fon-2018-0121","article-title":"Accelerating drug development in pediatric cancer: A novel Phase I study design of venetoclax in relapsed\/refractory malignancies","volume":"14","author":"Place","year":"2018","journal-title":"Future Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1111\/bjh.16682","article-title":"Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation","volume":"189","author":"Raedler","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e28398","DOI":"10.1002\/pbc.28398","article-title":"Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia","volume":"67","author":"Winters","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","article-title":"Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41375-022-01746-3","article-title":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","volume":"37","author":"Cheung","year":"2022","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia","volume":"79","author":"Comeaux","year":"2019","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41388-022-02196-y","article-title":"Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax","volume":"41","author":"Fidyt","year":"2022","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.ejca.2012.01.037","article-title":"Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth","volume":"48","author":"Lamers","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41416-020-0795-9","article-title":"A direct comparison of selective BH3-mimetics reveals BCL-X","volume":"122","author":"Bierbrauer","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eaao4680","DOI":"10.1126\/scitranslmed.aao4680","article-title":"Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma","volume":"10","author":"Lochmann","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1535-7163.MCT-20-0666","article-title":"High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells","volume":"20","author":"Vernooij","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-20-0710","article-title":"Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified NeuroblastomaVenetoclax Combos Effective in MYCN-amplified Neuroblastoma","volume":"20","author":"Dalton","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3324\/haematol.2014.109892","article-title":"Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia","volume":"100","author":"Niemeyer","year":"2015","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100840","DOI":"10.1016\/j.neo.2022.100840","article-title":"The kinetics of blast clearance are associated with copy number alterations in childhood B-cell acute lymphoblastic leukemia","volume":"35","author":"Lejman","year":"2023","journal-title":"Neoplasia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41375-018-0176-z","article-title":"The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL","volume":"33","author":"Kampen","year":"2019","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1080\/10428194.2021.1897807","article-title":"Venetoclax with chemotherapy in relapse\/refractory early T-cell precursor acute lymphoblastic leukemia","volume":"62","author":"Arora","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-021-04530-y","article-title":"Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia","volume":"101","author":"Kong","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Yang","year":"2022","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3026(21)00205-2","article-title":"Is venetoclax the new backbone of acute myeloid leukaemia therapy?","volume":"8","author":"Jain","year":"2021","journal-title":"Lancet Haematol."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/4\/745\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:18:56Z","timestamp":1760123936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/10\/4\/745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["children10040745"],"URL":"https:\/\/doi.org\/10.3390\/children10040745","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}